Probiotics: An emerging therapy

Current Pharmaceutical Design

Volumn 11, Issue 1, 2005, Pages 3-10

  O'Sullivan, Gerald C ^a   Kelly, P ^a   O'Halloran, S ^a   Collins, C ^a   Collins, J K ^a   Dunne, C ^a   Shanahan, F ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Colon cancer; Enteric microflora; Inflammatory bowel disease; Mucosal adherence; Pouchitis; Prebiotics; Probiotics; Synbiotics

Indexed keywords

PROBIOTIC AGENT;

BACTERIUM; BACTERIUM ADHERENCE; DIARRHEA; DIET SUPPLEMENTATION; DIGESTIVE SYSTEM; ECOSYSTEM; ENTERITIS; EVOLUTION; FOOD INTAKE; GASTROINTESTINAL DISEASE; HEALTH PROMOTION; HUMAN; ILEITIS; IMMUNOMODULATION; INTESTINE FLORA; LACTOBACILLUS; METABOLISM; MICROORGANISM; MUCOSAL IMMUNITY; NUTRIENT SUPPLY; PRIORITY JOURNAL; REVIEW; VALIDATION PROCESS;

ANIMALS; BIOLOGICAL THERAPY; GASTROINTESTINAL DISEASES; HUMANS; PROBIOTICS;

EID: 12144265966     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053382368     Document Type: Review

References (81)

1. Fuller R. A review: probiotics in man and animals. J Appl Bacteriol 1989; 66: 365-78.
2. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998; 39: 237-238.
3. Dunne C, Murphy L, Flynn S, O'Mahony L, O'Halloran D, Feeney M, et al. Probiotics; from myth to reality. Demonstration of functionality in animal models and in human clinical trials. Antione Vonleeuvenhoekh 1999; 76: 279-292.
4. Gorbach S. Probiotics and Gastrointestinal health. Am J Gastroenterol 2000; 95(1): 2-4.
5. Gionchetti P, Rizello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of Pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124(5): 1202-9.
6. Heller F, Duchmann R. Intestinal flora and mucosal immune responses. Int J Med Microbiol 2003; 293(1): 77-86.
7. Bengmark S. Colonic Food: Pre-and Probiotics. Am J Gastroenterol 2000; 95(1): Suppl 5-7.
8. Collins MD, Gibson GR. Probiotics, prebiotics and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69(5): 1052S-1057S.
9. Tannock GW. A fresh look at the intestinal microflora, in Probiotics a critical revie., Horizon Scientific Press Wymondham, UK, Tannock GW 2000; 5-14.
10. McCracken VJ, Gaskins HR. In: Tannock GW Ed, Probiotics and the immune System in Probiotics a critical review. Horizon Scientific Press, Wymondham, UK 2000; 85-111.
11. Berg RD, Savage DC. Immune responses of specific pathogen-free and gnotobiotic mice to antigens of indigenous and nonindigenous microorganisms. Infect Immun 1975; 11: 320-329.
12. Cebra JJ. Influences of microbiota on Intestinal immune system development. Am J Clin Nutr 1999; 69: 1046S-1051S.
13. Umesaki Y, Setoyama H. Structure of the intestinal flora responsible for development of the gut immune system in a rodent model. Microbes Infect 2000; 2(11): 1343-51.
14. Ward DM, Weller R, Bateson MM. 16S rRNA sequences reveal numerous uncultured micro-organisms a natural community. Nature 1990; 345: 63-65.
15. Conway PL. In: Ginson GR Ed, Microbial Ecology of the Human Large Intestine. In Human Colonic Bacteria: Role in Nutrition, Physiology and Pathology. MacFarlane GT., Boca Raton: CRC Press 1995; 1-24.
16. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996; 434: 430-435.
17. Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis 2001; 7(2): 136-145.
18. Cummings JH, Pomare EW, Branch JW, Naylor CPE, Macfarlane GT. Short chain fatty acids in human large intestine portal, hepatic and venous blood. Gut 1987; 28: 1221-1227.
19. Cummings JH, Macfarlane GT. Review: The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 1991; 70: 443-459.
20. Dunne C, O'Mahony L, Murphy L, Thornton G, Morrissey D, O'Halloran S, et al. In vitro selection criteria for probiotic strains-Correlation with in vivo findings. American Journal of Clinical Nutrition 2001; 73: 386.
21. Binder JH, Metha P. Short chain fatty acids stimulate active sodium and chloride absorption in vitro in the rat distal colon. Gastroenterology 1989; 96: 989-996.
22. Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel syndrome. Lancet 1994; 343: 373-376.
23. Macfarlane S, Macfarlane GT. In: Gibson GR Ed, Proteolysis and amino acid fermentation in: Human Colonic Bacteria: Role in Nutrition, Physiology and Pathology. Macfarlane GT, Boca Raton: CRC Press 1995; 75-100.
24. Pool-Zobel BL, Neudecker C, Domizlaff I, Ji S, Schillinger U, Rumney C, et al. Lactobacillus and Bifidobacterium mediated antigenotoxicity in the colon of rats. Nutr Cancer 1996; 26: 365-380.
25. Rowland IR, Rumney CJ, Coutts JT, Lievense LC. Effect of Bifidobacterium Longum and inulin on gut bacterial metabolism and carcinogen induced aberrant crypt foci in rats. Carcinogenesis 1998; 19: 281-285.
26. Schiffrin EJ, Blum S. Interactions between the microbiota and the intestinal mucosa. Eur J Clin Nutr 2002; 56 (3): S60-4.
27. Dugas B, Mercenier A, Lenoir-Wijnkoop I, Arnaud C, Dugas N, Postaire E. Immunity and Probiotics Immunology Today 1999; 20(9): 387-390.
28. Stark PL, Lee A. The microbial ecology of the large bowel of breast-fed and formula-fed infants during the first year of life. J Med Microbiol 1982; 15: 189-203.
29. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 1999; 69: 1035-1045.
30. Shroff KE, Meslin K, Cebra JJ. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immun 1995; 63: 3904-3913.
31. Helgeland L, Vaage JT, Rolstad B, Midtvedt T, Brandtzaeg P. Microbial colonization influences composition and T-cell receptor V beta repertoire of intraepithelial lymphocytes in rat intestine. Immunology 1996; 89: 494-501.
32. Cebra JJ, Bhargava Periwal S, Lee G, Lee F, Shroff KE. Development and maintenance of the gut-associated lymphoid tissue (GALT): the roles of enteric bacteria and viruses. Dev Immunol 1998; 6: 13-18.
33. Eaton SB, Konner M. Paleolithic Nutrition. A consideration of its nature and current implications. N Engl J Med 1985; 312: 283-289.
34. Niers LE, Rijkers G, Knol EF, Meijer Y, Hockstra MO. Probiotics for prevention of atopic disease? Lancet 2003; 361(9372): 1869-71.
35. Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36(6): 775-80.
36. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000; 95(1): S11-3.
37. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Infect Dis 2002; 34(5): 628-33.
38. Alam NH, Ashraf H. Treatment of infectious diarrhea in children. Paediatr Drugs 2003; 5(3): 151-65.
39. Saaverda JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344: 1046-1049.
40. Ribeiro H, Vanderhoof JA. Reduction of diarrheal illness following administration of Lactobacillus plantarum 299v in a day-care facility. J Paediatr Gastroenterol Nutr 1998; 26: 561.
41. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002; 88(1): S39-49.
42. Cunningham Rundles S, Ahrne S, Bengmark S, Johann-Liang R, Marshall F, Metakis L, et al. Probiotics and Immune Response. Am J Gastroenterol 2000; 95: 22S-25S.
43. Gaon D, Garmendia C, Murrielo NO, de Cucco Games A, Cerchio A, Quintas R, et al. Effect of Lactobacillus strains (L. cosei and L. acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina (B Aires) 2002; 62(2): 159-63.
44. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary open label study. J Paediatr. Gastroenterol Nutr 2002; 31(4): 453-7.
45. O'Mahony L, McCarthy J, Feeney M, Dunne C, Kiely B, O'Sullivan GC, et al. Immunologic response of a novel probiotic organism in patients with active Crohn's disease. Gastroenterology 2000; 118: A853.
46. Shanahan F. Probiotics in inflammatory bowel disease: is there a scientific rationale. Inflammatory Bowel Disease 2000; 6: 107-115.
47. Mitsuyama K, Toyonaga A, Sata M. Intestinal microflora as a therapeutic target in inflammatory bowel disease. Gastroenterol 2002; 37(14): 73-7.
48. Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2003; 36(2): 111-9.
49. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease:current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol 2001; 234: 29-40.
50. Madsen KL, Doyle JS, Jewel LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin10 gene-deficient mice. Gastroenterology 1999; 116: 1107-1114.
51. Murphy L, Byrne F, Collins JK, Shanahan F, O'Sullivan GC, Aranda R. Evaluation and Characterisation of probiotic therapy in CD45H1 transfer model of colitis. Gastroenterology 1999; 116(4): A780.
52. O'Mahony L, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgibbon J, et al. Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL10 Knockout Mice. Alimentary Pharmacology and Therapeutics 2001; 25: 1219-1225.
53. Kruis W, Schütz E, Fric P, Fixa B, Judmaiers G, Stolte M. Double comparison of an oral Escharichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858.
54. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon ATR. Non- pathogenic Eschirichia coli versus mesalazine for treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639.
55. Kelly KA. "Pouchitis": new routes of research and signification. Ann Chir 1993; 47(10): 1049-1042.
56. Penna C, Tiret E, Kartheuser A, Hannoun L, Nordlinger B, Parc R. Function of ilea J pouch-anal anastamosis in patients with familial adenomatosis polyposis. Br J Surg 1993; 80(6): 765-767.
57. Kuhbacher T, Schreiber S, Runkel N. Pouchitis: Pathophysiology and treatment. Int J Colorectal Dis 1998; 13(5-6): 196-207.
58. Gionchetti P, Rizello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral Bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double blind, placebo controlled trial. Gastroenterology 2000; 119(2): 305-309.
59. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG oil ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17(4): 509-15.
60. Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001; 30(1): 49-52
61. Darouiche RO, Donovan WH, Del Terzo M, Thorby JI, Rudy DC, Hull RA. Pilot trial of bacterial interferance for preventing urinary tract infection. Urology 2001; 58(3): 339-344.
62. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30: 1604-1610.
63. Pessi T, Sutas Y, Hurme M, Isolauri E. Interleukin -10 generation in atopic 'children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy 2000; 30(12): 1804-8.
64. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001; 357 (9262): 1076-9.
65. Rafter J. Probiotics and colon cancer. Best Pract Res Clin Gastroenterol 2003; (5): 849-59.
66. Challa A, Rao DR, Chawan CB, Shackleford L. Bifidobacterium Longum and lactulose suppress azoxymethane - induced colonic aberrant crypt foci in rats. Carcinogenesis 1997; 18: 517-521.
67. Reddy BS. Prevention of colon cancer by pre and probiotics: evidence from laboratory studies. Br J Nutr 1998; 80: S219-S223.
68. Femia AP, Luceri C, Dolara P, Giannini A, Biggeri A, Salvadori M, et al. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with tire probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 2002; 11: 1953-60.
69. Eyssen H. Role of gut microflorain metabolism of Lipids and Sterols. Proc Nutr Soc 1973; 32: 50-63.
70. Rasic JL, Vujicic IF, Skrinjar M, Vulic M. Assimilation of cholesterol by some cultures of lactic acid bacteria and bifidobacteria. Biotechnol Lett 1992; 14: 39-44.
71. Taylor CRJ, Williams CM. Effects of probiotics and prebiotics on blood lipids Br J Nutr 1998; 80: 225S-230S.
72. Roberfroid MB. Prebiotics and Probiotics: are they functional foods? Am J Clin Nutr 2000; 71: 1682S-1694S.
73. Sanders ME. Consideration for rise of probiotics to modulate human health. J Nutr 2000; 130: 384S-390S.
74. Naruszewicz M, Johansson ML, Zapolska-Downar D, Bukowska H. Effect of Lactobacillus plantarum 299v oil cardiovascular disease risk factors in smokers. Am J Clin Nutr 2002; 76(6): 1249-55.
75. Cross ML. Microbes versus microbes: immune signals generated by probiotic lactobacilli and their role in protection against microbial pathogens. FEMS Immunol Med Microbiol 2002; 34(4): 245-53.
76. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361 (9356): 512-9.
77. Seegers JF. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 2002; (12): 508-15.
78. Kruisselbrink A, Heijne Den Bak-Glashonwer MJ, Havenith CE, Thole JE, Janssen R. Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses. Clin Exp Immunol 2001; 126(1): 2-8.
79. Andoh A, Tsujikawa T, Fujiyama Y. Role of dietary fiber and short-chain fatty acids in the colon. Curr Pharm Design 2003; 9(4): 347-58.
80. Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Design 2003; 9(4): 333-46.
81. Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Design 2003; 9(14): 1107-13.